Enterprise Qualification and Product Registration in Argentina

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

In Argentina’s regulatory architecture, enterprise qualification (habilitación) and product registration (registro) are two independent market-access tracks, each indispensable. Enterprise qualification authorizes a company to engage in manufacturing and/or import activities; product registration authorizes a specific product to be placed on the market.

The sequencing relationship is: enterprise qualification is a precondition for product registration (the applicant must be a qualified local company), but the two tracks can be advanced in parallel. The most common disconnect seen in practice is a product dossier that is fully ready while the holder’s enterprise qualification is still being processed — a mismatch that delays the filing start by months and pushes the entire launch plan back with it.

Because the two tracks are independent, each has its own dossier, its own procedure and its own timeline, and neither can borrow from the other. A distributor or subsidiary may already hold a registration portfolio while lacking the qualification to import new lines; conversely, a newly qualified holder may have no registrations in force at all. Treating the two as a single merged license is the root of most sequencing errors seen in Argentina market-entry planning, and untangling them early saves months later.

2. Legal basis

The instruments below govern enterprise qualification, the GMP certificate nested inside it, the simplified declaration channel, and the product registration applicant requirement.

InstrumentReference / numberPublication dateProvisions
Authorization of operating qualification for manufacturing/import enterprisesDisposición ANMAT 2319/2002 (T.O. 2004)2002 (consolidated text 2004)Qualification authorization provisions
Good Manufacturing Practices (BPF/GMP)Disposición ANMAT 3266/20132013BPF compliance certificate provisions
Enterprise qualification proceduresDisposición ANMAT 7425/2013; 2096/20222013 / 2022Standard procedure provisions
Simplified channel for low-risk enterprise qualificationDisposición ANMAT 8799/2025Published November 28, 2025, effective 60 administrative business days after publicationSworn declaration provisions
Principal product registration instrumentDisposición ANMAT 64/2025Published in the Official Gazette on January 13, 2025Registration applicant provisions

3. Expert insights

Insight 1: a GMP requirement is nested inside enterprise qualification itself. The holder must not only obtain the operating qualification under 2319/2002 but also hold a BPF compliance certificate issued by ANMAT under 3266/2013. The BPF certificate application procedure is governed by 7425/2013 and 2096/2022 and requires its own scheduling. Enterprise qualification is therefore in practice two actions: qualification plus GMP, and timelines should be built for both.

Insight 2: 8799/2025, published on November 28, 2025, opens a third road for low-risk enterprises. Companies manufacturing and/or importing Class I/II devices and Group A/B IVD may opt to substitute a sworn declaration for the traditional procedures of 2319/02 (T.O. 2004), 7425/13 and 2096/22, obtaining authorization upon submission on the ANMAT digital platform. The GMP obligation is not waived by the simplification, however — the shortcut touches paperwork, not standards.

Insight 3: the optimal schedule for the two parallel tracks is qualification half a step ahead. Product dossier preparation (including the legalization chain) usually takes the longest, while enterprise qualification can be compressed substantially under the 8799/2025 channel. The ideal sequence: start the qualification first (especially through the sworn declaration channel), prepare the product dossier in parallel, and file the product registration immediately once the qualification is in place.

Coordinating the two tracks is primarily a scheduling exercise, and the schedule depends on two early judgments: which qualification channel the holder will use, and how long the product dossier’s legalization chain will take. The recommendations below sequence the work so that neither track idles while waiting for the other, and so that the filing date is set by the slower of the two rather than by optimism.

4. Practical recommendations

  1. Determine first which qualification channel the holder will use. If only Class I/II devices and Group A/B IVD are involved, evaluate the 8799/2025 sworn declaration channel; where Class III/IV devices or Group C/D IVD are involved, the traditional procedures still apply.
  2. Schedule the BPF certificate within the qualification timeline. Set separate milestones for the qualification and the GMP actions; do not merge them into a single estimate.
  3. Start the product dossier at the same time as the qualification. The legalization chain (CFS, apostille and translation of the authorization) takes the longest and should begin together with the qualification application.
  4. Fix qualification-maintenance duties in the holder agreement. Who handles changes, renewals and additions of premises to the qualification, and by when, must be written into the agreement.

5. Verification checklist

Confirm each item below when planning the two parallel tracks.

  • □ Enterprise qualification and product registration are managed as two independent tracks
  • □ Whether the holder will use the traditional procedures or the 8799/2025 simplified channel has been confirmed
  • □ The BPF compliance certificate (3266/2013) application has been scheduled separately
  • □ The legalization chain of the product dossier has started in parallel with the qualification application
  • □ The qualification scope covers the highest risk class of the products to be filed
  • □ The holder agreement assigns responsibility for qualification maintenance and changes

Because qualification maintenance continues for as long as the products are marketed, treat this checklist as cyclical: confirm the qualification scope whenever a new product class is added to the portfolio, and re-confirm the BPF certificate and declaration status at each renewal point. A cyclical review keeps both tracks permanently aligned instead of periodically colliding.

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and labeling localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the developments of regulatory authorities worldwide. All published content follows the drafting standard of conclusions first, traceable legal basis, and verifiable figures. For an Argentina or MERCOSUR market-access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail